Pulmonary arterial hypertension in congenital heart diseases

Seminars in Respiratory and Critical Care Medicine

Volumn 30, Issue 4, 2009, Pages 421-428

  Beghetti, Maurice ^a,b   Tissot, Cecile ^a  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

^b Hopital des Enfants Hopitaux universitaires de Geneve   (Switzerland)

Author keywords

Congenital; Eisenmenger syndrome; Heart defect; Hypertension; Pulmonary

Indexed keywords

BOSENTAN; ENDOTHELIN RECEPTOR ANTAGONIST; PHOSPHODIESTERASE V INHIBITOR; PLACEBO; PROSTACYCLIN; PROSTACYCLIN DERIVATIVE;

CENTRAL VENOUS CATHETER; CLINICAL TRIAL; CONGENITAL HEART DISEASE; DISEASE CLASSIFICATION; DRUG RESPONSE; EISENMENGER COMPLEX; HEART INJURY; HEART LUNG TRANSPLANTATION; HEART SURGERY; HUMAN; LUNG BLOOD FLOW; LUNG HEMODYNAMICS; LUNG PRESSURE; MORBIDITY; MORTALITY; PATHOPHYSIOLOGY; POSTOPERATIVE PERIOD; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PULMONARY HYPERTENSION; REVIEW;

ADULT; BLOOD PRESSURE; CHILD; DRUG DELIVERY SYSTEMS; EISENMENGER COMPLEX; ENDOTHELIUM, VASCULAR; HEART DEFECTS, CONGENITAL; HUMANS; HYPERTENSION, PULMONARY;

EID: 68049110645     PISSN: 10693424     EISSN: 10989048     Source Type: Journal    
DOI: 10.1055/s-0029-1233311     Document Type: Review

References (56)

1. Beghetti M. Congenital heart disease and pulmonary hypertension. Rev Port Cardiol 2004;23:273-281 (Pubitemid 38523875)
2. Granton JT, Rabinovitch M. Pulmonary arterial hypertension in congenital heart disease. Cardiol Clin 2002;20:441-457, vii
3. Kidd L, Driscoll DJ, Gersony WM, et al. Second natural history study of congenital heart defects: results of treatment of patients with ventricular septal defects. Circulation 1993;87 (2, Suppl):I38-I51 (Pubitemid 23042117)
4. Diller GP, Dimopoulos K, Broberg CS, et al. Presentation, survival prospects, and predictors of death in Eisenmenger syndrome: a combined retrospective and case-control study. Eur Heart J 2006;27:1737-1742 (Pubitemid 44025362)
5. Haworth SG. Pulmonary vascular disease in different types of congenital heart disease: implications for interpretation of lung biopsy findings in early childhood. Br Heart J 1984;52:557-571
6. Galiè N, Torbicki A, Barst R, et al. Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. Eur Heart J 2004;25:2243-2278
7. Diller GP, Gatzoulis MA. Pulmonary vascular disease in adults with congenital heart disease. Circulation 2007;115:1039-1050 (Pubitemid 46328298)
8. Simonneau G, Galiè N, Rubin LJ, et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol 2004;43 (12, Suppl S):5S-12S
9. Galie N, Manes A, Palazzini M, et al. Management of pulmonary arterial hypertension associated with congenital systemic-to-pulmonary shunts and Eisenmenger's syndrome. Drugs 2008;68:1049-1066 (Pubitemid 351693675)
10. van Albada ME, Berger RM. Pulmonary arterial hypertension in congenital cardiac disease - the need for refinement of the Evian-Venice classification. Cardiol Young 2008;18:10-17
11. Rabinovitch M, Bothwell T, Hayakawa BN, et al. Pulmonary artery endothelial abnormalities in patients with congenital heart defects and pulmonary hypertension: a correlation of light with scanning electron microscopy and transmission electron microscopy. Lab Invest 1986;55:632-653 (Pubitemid 17231129)
12. Rabinovitch M. Pulmonary hypertension: pathophysiology as a basis for clinical decision making. J Heart Lung Transplant 1999;18:1041-1053
13. Haworth SG. Pulmonary vascular disease in ventricular septal defect: structural and functional correlations in lung biopsies from 85 patients, with outcome of intracardiac repair. J Pathol 1987;152:157-168
14. Newfeld EA, Paul MM, Muster AJ, Idriss FS. Pulmonary vascular disease in complete transposition of the great arteries: a study of 200 patients. Am J Cardiol 1974;34:75-82
15. Eisenmenger V. Die angeborenen defects des kammerscheidewand des herzen. Z Klin Med 1897;32:1-28
16. Wood P. The Eisenmenger syndrome or pulmonary hypertension with reversed central shunt, I. BMJ 1958;46:701-709
17. Daliento L, Somerville J, Presbitero P, et al. Eisenmenger syndrome: factors relating to deterioration and death. Eur Heart J 1998;19:1845-1855 (Pubitemid 28556655)
18. Diller GP, Dimopoulos K, Okonko D, et al. Exercise intolerance in adult congenital heart disease: comparative severity, correlates, and prognostic implication. Circulation 2005;112:828-835 (Pubitemid 41170068)
19. Pietra GG. The pathology of pulmonary hypertension. In: Rubin LJ, Rich S, eds. Primary Pulmonary Hypertension. New York: Marcel Dekker; 1997:19-61
20. Vongpatanasin W, Brickner ME, Hillis LD, Lange RA. The Eisenmenger syndrome in adults. Ann Intern Med 1998;128:745-755
21. Hopkins WE, Ochoa LL, Richardson GW, Trulock EP. Comparison of the hemodynamics and survival of adults with severe primary pulmonary hypertension or Eisenmenger syndrome. J Heart Lung Transplant 1996;15(1 Pt 1):100-105
22. Hopkins WE. The remarkable right ventricle of patients with Eisenmenger syndrome. Coron Artery Dis 2005;16:19-25 (Pubitemid 40279593)
23. Humbert M, Morrell NW, Archer SL, et al. Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol 2004;43(12, Suppl S):13S-24S
24. Deanfield J, Thaulow E, Warnes C, et al; Task Force on the Management of Grown Up Congenital Heart Disease, European Society of CardiologyESC Committee for Practice Guidelines. Management of grown up congenital heart disease. Eur Heart J 2003;24:1035-1084
25. Broberg CS, Ujita M, Prasad S, et al. Pulmonary arterial thrombosis in eisenmenger syndrome is associated with biventricular dysfunction and decreased pulmonary flow velocity. J Am Coll Cardiol 2007;50:634-642 (Pubitemid 47199004)
26. Berman EB, Barst RJ. Eisenmenger's syndrome: current management. Prog Cardiovasc Dis 2002;45:129-138
27. Stoica SC, McNeil KD, Perreas K, et al. Heart-lung transplantation for Eisenmenger syndrome: early and long-term results. Ann Thorac Surg 2001;72:1887-1891 (Pubitemid 34001434)
28. Adriaenssens T, Delcroix M, Van Deyk K, Budts W. Advanced therapy may delay the need for transplantation in patients with the Eisenmenger syndrome. Eur Heart J 2006;27:1472-1477 (Pubitemid 43998082)
29. Beghetti M, Black SM, Fineman JR. Endothelin-1 in congenital heart disease. Pediatr Res 2005;57(5 Pt 2):16R-20R
30. Galié N, Manes A, Branzi A. The endothelin system in pulmonary arterial hypertension. Cardiovasc Res 2004;61:227-237 (Pubitemid 38091763)
31. Galiè N, Beghetti M, Gatzoulis MA, et al; Bosentan Randomized Trial of Endothelin Antagonist Therapy-5 (BREATHE-5) Investigators. Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study. Circulation 2006;114:48-54
32. Gatzoulis MA, Beghetti M, Galiè N, et al; BREATHE-5 Investigators. Longer-term bosentan therapy improves functional capacity in Eisenmenger syndrome: results of the BREATHE-5 open-label extension study. Int J Cardiol 2008;127:27-32 (Pubitemid 351707527)
33. Brun H, Thaulow E, Fredriksen PM, Holmstrom H. Treatment of patients with Eisenmenger's syndrome with Bosentan. Cardiol Young 2007;17:288-294 (Pubitemid 46784629)
34. Benza RL, Rayburn BK, Tallaj JA, et al. Efficacy of bosentan in a small cohort of adult patients with pulmonary arterial hypertension related to congenital heart disease. Chest 2006;129:1009-1015
35. Schulze-Neick I, Gilbert N, Ewert R, et al. Adult patients with congenital heart disease and pulmonary arterial hypertension: first open prospective multicenter study of bosentan therapy. Am Heart J 2005;150:716 (Pubitemid 41396505)
36. Gatzoulis MA, Rogers P, Li W, et al. Safety and tolerability of bosentan in adults with Eisenmenger physiology. Int J Cardiol 2005;98:147-151 (Pubitemid 40169865)
37. Christensen DD, McConnell ME, Book WM, Mahle WT. Initial experience with bosentan therapy in patients with the Eisenmenger syndrome. Am J Cardiol 2004;94:261-263
38. Diller GP, Dimopoulos K, Kaya MG, et al. Long-term safety, tolerability and efficacy of bosentan in adults with pulmonary arterial hypertension associated with congenital heart disease. Heart 2007;93:974-976 (Pubitemid 47122051)
39. D'Alto M, Vizza CD, Romeo E, et al. Long term effects of bosentan treatment in adult patients with pulmonary arterial hypertension related to congenital heart disease (Eisenmenger physiology): safety, tolerability, clinical, and haemodynamic effect. Heart 2007;93:621-625 (Pubitemid 46707118)
40. van Loon RL, Hoendermis ES, Duffels MG, et al. Longterm effect of bosentan in adults versus children with pulmonary arterial hypertension associated with systemicto- pulmonary shunt: does the beneficial effect persist? Am Heart J 2007;154:776-782
41. Apostolopoulou SC, Manginas A, Cokkinos DV, Rammos S. Long-term oral bosentan treatment in patients with pulmonary arterial hypertension related to congenital heart disease: a 2-year study. Heart 2007;93:350-354 (Pubitemid 46579526)
42. Rosenzweig EB, Kerstein D, Barst RJ. Long-term prostacyclin for pulmonary hypertension with associated congenital heart defects. Circulation 1999;99:1858-1865 (Pubitemid 29181415)
43. Fernandes SM, Newburger JW, Lang P, et al. Usefulness of epoprostenol therapy in the severely ill adolescent/adult with Eisenmenger physiology. Am J Cardiol 2003;91:632-635 (Pubitemid 36263277)
44. Frost AE, Quiñones MA, Zoghbi WA, Noon GP. Reversal of pulmonary hypertension and subsequent repair of atrial septal defect after treatment with continuous intravenous epoprostenol. J Heart Lung Transplant 2005;24:501-503
45. Schwerzmann M, Zafar M, McLaughlin PR, Chamberlain DW, Webb G, Granton J. Atrial septal defect closure in a patient with "irreversible" pulmonary hypertensive arteriopathy. Int J Cardiol 2006;110:104-107
46. Limsuwan A, Pienvichit P, Khowsathit P. Beraprost therapy in children with pulmonary hypertension secondary to congenital heart disease. Pediatr Cardiol 2005;26:787-791 (Pubitemid 43130171)
47. Ivy DD, Doran AK, Smith KJ, et al. Short- and long-term effects of inhaled iloprost therapy in children with pulmonary arterial hypertension. J Am Coll Cardiol 2008;51:161-169
48. Agapito AF, Sousa L, Oliveira JA, Feliciano J, Cacela D, Quininha J. Eisenmenger syndrome in the adult: experience with new drugs for the treatment of pulmonary hypertension. Rev Port Cardiol 2005;24:421-431 (Pubitemid 40675827)
49. Okyay K, Cemri M, Boyac B, Yalcn R, Cengel A. Use of long-term combined therapy with inhaled iloprost and oral sildenafil in an adult patient with eisenmenger syndrome. Cardiol Rev 2005;13:312-314 (Pubitemid 41579597)
50. Chau EM, Fan KY, Chow WH. Effects of chronic sildenafil in patients with Eisenmenger syndrome versus idiopathic pulmonary arterial hypertension. Int J Cardiol 2007;120:301-305 (Pubitemid 47069563)
51. Garg N, Sharma MK, Sinha N. Role of oral sildenafil in severe pulmonary arterial hypertension: clinical efficacy and dose response relationship. Int J Cardiol 2007;120:306-313 (Pubitemid 47069567)
52. Mukhopadhyay S, Sharma M, Ramakrishnan S, et al. Phosphodiesterase-5 inhibitor in Eisenmenger syndrome: a preliminary observational study. Circulation 2006;114:1807-1810 (Pubitemid 44673355)
53. Lim ZS, Salmon AP, Vettukattil JJ, Veldtman GR. Sildenafil therapy for pulmonary arterial hypertension associated with atrial septal defects. Int J Cardiol 2007;118:178-182 (Pubitemid 46604774)
54. Oechslin E, Kiowski W, Schindler R, Bernheim A, Julius B, Brunner-La Rocca HP. Systemic endothelial dysfunction in adults with cyanotic congenital heart disease. Circulation 2005;112:1106-1112 (Pubitemid 41216116)
55. Lunze K, Gilbert N, Mebus S, et al. First experience with an oral combination therapy using bosentan and sildenafil for pulmonary arterial hypertension. Eur J Clin Invest 2006;36(Suppl 3):32-38 (Pubitemid 44179779)
56. Galiè N, Rubin Lj, Hoeper M, et al. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. Lancet 2008;371:2093-2100 (Pubitemid 351902178)